Printer Friendly

BIOWHITTAKER AND BIOTECHNOLOGY RESEARCH INSTITUTE TO PRODUCE BOTULISM ANTITOXIN FOR U.S. ARMY

 WALKERSVILLE, Md., June 15 /PRNewswire/ -- BioWhittaker, Inc. (NYSE: BWI), announced today that the company, in conjunction with Organon Teknika/Biotechnology Research Institute, has been awarded a three-year contract to produce a botulism antitoxin for the United States Army Medical Materiel Development Activity. The antitoxin will be a treatment for the severe and sometimes fatal poisoning caused by the neurotoxins produced by the bacterium Clostridium botulinum. The contract is expected to generate sales for BioWhittaker of $4 million to $5 million over a three-year period.
 BioWhittaker, Inc., develops and produces clinical diagnostic testing systems, cell culture products and endotoxin detection assays for the international healthcare and biotechnology markets.
 -0- 6/15/93
 /CONTACT: Susan Walden, director of communications, BioWhittaker, 301-898-7025, ext. 2559/
 (BWI)


CO: BioWhittaker, Inc.; Organon Teknika/Biotechnology Research
 Institute ST: Maryland IN: MTC SU:


TW -- DC004 -- 1938 06/15/93 08:03 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jun 15, 1993
Words:144
Previous Article:NEW BOX USES 40 PERCENT LESS CARDBOARD; A BOON TO ECOLOGY...AND BUSINESS, TOO
Next Article:KAISERSLAUTERN VENTURE TO PRODUCE POWER STEERING GEARS
Topics:


Related Articles
BOEHRINGER INGELHEIM BIOWHITTAKER OFFERS TOUR OF NEW BELGIUM FACILITY TO BIOTECHNOLOGY AND PHARMACEUTICAL CUSTOMERS
BIOWHITTAKER ANNOUNCES THE APPOINTMENT OF DR. FREDRIC SIMON AS SENIOR DIRECTOR OF RESEARCH AND DEVELOPMENT
BIOWHITTAKER ANNOUNCES STRONG THIRD QUARTER EARNINGS
BioWhittaker Announces Improved Third Quarter Earnings
BioWhittaker Retains Alex. Brown to Advise on Strategic Alternatives
BioWhittaker and Human Cell Culture Center Announce Distribution Agreement
DynCorp Team Wins $322 Million Defense Contract to Protect Troops from Biological Warfare Through Development of FDA-Licensed Vaccines
Genencor Awarded $2 Million Contract for Biodefense Work.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters